Cardeon Corp.
This article was originally published in Start Up
Executive Summary
The only known cerebro-protectant that has been shown to reduce the severity of stroke and ischemia is cold. Cardeon is therefore developing devices based on the principle of hypothermia to protect the brain against damage during or after cardiovascular and other surgical procedures. The company's technology also segments the brain circulation from the corporeal circulation to keep the brain free of emboli.
You may also be interested in...
Temperature Management Devices Are Hot
Doctors have long theorized that being able to precisely warm (hyperthermia) and cool (hypothermia) patients, depending on their conditions and surroundings, would be beneficial in a variety of neurological and cardiovascular procedures. This has given rise to a group of medical device companies formed in the mid-to-late 1990s dedicated to developing temperature management systems. The big question has ben whether clinical data would validate the bets these companies made in this space. Early clinical data released recently has been positive, and large companies are interested in this area, sparking the first major temperature management deal.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”